Your browser doesn't support javascript.
loading
Protocol of the development of a core outcome set for stroke in multidimensional value assessment of traditional Chinese medicine.
Yuan, Jing; Yang, Lei; Li, Minghui; Bai, Jingwen; Cheng, Yinjie; Feng, Yuan; Zhao, Jing; Lu, Kevin.
Afiliação
  • Yuan J; Minhang Hospital, School of Pharmacy, Fudan University, Shanghai, People's Republic of China jyuan@fudan.edu.cn lu32@email.sc.edu zhao_jing@fudan.edu.cn.
  • Yang L; Strategic Support Force Medical Center, Beijing, People's Republic of China.
  • Li M; The University of Tennessee Health Science Center, Memphis, Tennessee, USA.
  • Bai J; Department of Clinical Pharmacy and Drug Administration, School of Pharmacy, Fudan University, Shanghai, People's Republic of China.
  • Cheng Y; Department of Clinical Pharmacy and Drug Administration, School of Pharmacy, Fudan University, Shanghai, People's Republic of China.
  • Feng Y; Department of Clinical Pharmacy and Drug Administration, School of Pharmacy, Fudan University, Shanghai, People's Republic of China.
  • Zhao J; Department of Neurology, Minhang Hospital, Fudan University, Shanghai, People's Republic of China jyuan@fudan.edu.cn lu32@email.sc.edu zhao_jing@fudan.edu.cn.
  • Lu K; Department of Clinical Pharmacy and Outcome Sciences, School of Pharmacy, University of South Carolina, Columbia, South Carolina, USA jyuan@fudan.edu.cn lu32@email.sc.edu zhao_jing@fudan.edu.cn.
BMJ Open ; 14(1): e079492, 2024 01 18.
Article em En | MEDLINE | ID: mdl-38238171
ABSTRACT

INTRODUCTION:

Stroke is the most common cause of death in China. In Chinese clinical practise, traditional Chinese medicine (TCM) and integrative medicine have been widely used as adjuvant therapies for the treatment of stroke. However, their clinical effectiveness, particularly their clinical value, has been inconsistent in the literature mainly because various outcome measures have been used and reported in clinical research. Hence, obtaining a comprehensive list of outcomes for TCM value assessment is crucial for a multidimensional value assessment. Therefore, the main objective of this protocol was to develop an outcome set used in health technology assessment (HTA) decision-making for TCM treatment of stroke. METHODS AND

ANALYSIS:

The outcome set will be developed in four phases (1) we will perform a systematic literature review to identify candidate outcomes that have been previously measured in published studies; (2) we will develop a comprehensive list of outcome measures by conducting a multistakeholder semistructured interview; (3) we will conduct two-round Delphi surveys to prioritise outcomes for each HTA domain; and (4) we will finalise the outcome sets by holding a ratification meeting with multiple stakeholder groups. The developed outcome set should be measured and reported as the minimum set of outcomes for HTA assessment for the TCM treatment of acute ischaemic stroke (AIS). ETHICS AND DISSEMINATION This protocol was reviewed and approved by the Institutional Review Board of the Minhang Hospital of Fudan University. Our findings will be shared at academic conferences and in peer-reviewed publications.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Isquemia Encefálica / Acidente Vascular Cerebral Tipo de estudo: Diagnostic_studies / Guideline / Health_technology_assessment / Prognostic_studies / Qualitative_research / Systematic_reviews Limite: Humans Idioma: En Revista: BMJ Open Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Isquemia Encefálica / Acidente Vascular Cerebral Tipo de estudo: Diagnostic_studies / Guideline / Health_technology_assessment / Prognostic_studies / Qualitative_research / Systematic_reviews Limite: Humans Idioma: En Revista: BMJ Open Ano de publicação: 2024 Tipo de documento: Article